Moukheibir Catherine 4
4 · MoonLake Immunotherapeutics · Filed Jul 7, 2025
Insider Transaction Report
Form 4
Moukheibir Catherine
Director
Transactions
- Exercise/Conversion
Option to Buy
2025-07-03−23,500→ 21,500 totalExercise: $12.25Exp: 2032-04-06→ Class A ordinary shares, par value $0.0001 per share (23,500 underlying) - Exercise/Conversion
Class A ordinary shares, par value $0.0001 per share
2025-07-03+23,500→ 23,500 total - Sale
Class A ordinary shares, par value $0.0001 per share
2025-07-03$48.79/sh−23,500$1,146,565→ 0 total
Footnotes (2)
- [F1]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $48.59 to $49.01. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F2]These options are fully vested.